TABLE 1

Characteristics of All Reports After Currently Licensed DTaP Vaccines in VAERS Among Persons Vaccinated From January 1, 1991, Through December 31, 2016 (Receipt March 17, 2017)

CharacteristicsNo. (%)
Total reports50 157a
Serious5627 (11.2)
Median age (interquartile range), mo19 (35)
Age <6 y46 836 (93.4)
Male sex25 781 (51.4)
Median onset interval (range), d1 (0–5115)
DTaP vaccines (n = 50 282)a
 DTaP (Infanrix)17 484 (34.8)
 DTaP (Daptacel)13 153 (26.2)
 DTaP-HepB-IPV (Pediarix)8906 (17.7)
 DTaP-IPV-Hib (Pentacel)5464 (10.9)
 DTaP-IPV (Kinrix)5275 (10.4)
 DTaP vaccines given in combination with other vaccines43 984 (87.7)
Most common vaccine combinations given concomitantlyb
 MMR II15 021 (34.6)
 Polio14 229 (32.4)
 Pneumococcal vaccine (Prevnar7)c11 794 (26.8)
 Varicella (Varivax)8772 (19.9)
 Rotavirus vaccine8266 (16.4)
 Hib (ActHib)7530 (17.1)
Type of reporter (n = 49 272)d
 Vaccine provider31 478 (62.8)
 Othere11 842 (23.6)
 Manufacturer3359 (6.7)
 Parent2593 (5.2)
 Subject recovered by the time VAERS form was submitted31 677 (63.2)
  • HepB, hepatitis B; MMR II, measles, mumps, and rubella II.

  • a Some individuals received >1 DTaP vaccine.

  • b Concomitant vaccines are not mutually exclusive.

  • c Prevnar 13 given with DTaP in 6427 (14.6%) reports not shown.

  • d Eight hundred and eighty-five reports with missing reporter information.

  • e Secretary or office assistant.